Benzylic oxidation of gemfibrozil-1-O-β-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition

Chemical Research in Toxicology

Volumn 22, Issue 7, 2009, Pages 1298-1309

  Baer, Brian R ^a   DeLisle, Robert Kirk ^a   Allen, Andrew ^a  

^a ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPROTEIN; BENZYL ALCOHOL; CYTOCHROME P450 2C8; DEUTERIUM; GEMFIBROZIL; GEMFIBROZIL 1 O BETA GLUCURONIDE; HEME; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; DRUG ACTIVATION; DRUG OXIDATION; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; OXIDATION; PROTEIN MODIFICATION;

ALKYLATION; ARYL HYDROCARBON HYDROXYLASES; CATALYTIC DOMAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; GEMFIBROZIL; GLUCURONATES; HEME; HUMANS; HYPOLIPIDEMIC AGENTS; MASS SPECTROMETRY; OXIDATION-REDUCTION; RECOMBINANT PROTEINS;

EID: 67650996771     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx900105n     Document Type: Article

References (39)

1. Backman, J. T., Kyrklund, C., Neuvonen, M., and Neuvonen, P. J. (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685-691.
2. Niemi, M., Backman, J. T., Neuvonen, M., and Neuvonen, P. J. (2003) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: Potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46, 347-351.
3. Niemi, M., Backman, J. T., Granfors, M., Laitila, J., Neuvonen, M., and Neuvonen, P. J. (2003) Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46, 1319-1323.
4. Jaakkola, T., Backman, J. T., Neuvonen, M., and Neuvonen, P. J. (2005) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin. Pharmacol. Ther. 77, 404-414.
5. Wen, X., Wang, J. S., Backman, J. T., Kivisto, K. T., and Neuvonen, P. J. (2001) Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. 29, 1359-1361.
6. Wang, J. S., Neuvonen, M., Wen, X., Backman, J. T., and Neuvonen, P. J. (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. 30, 1352-1356.
7. Lilja, J. J., Backman, J. T., and Neuvonen, P. J. (2005) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br. J. Clin. Pharmacol. 59, 433-439.
8. Shitara, Y., Hirano, M., Sato, H., and Sugiyama, Y. (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236.
9. Mano, Y., Usui, T., and Kamimura, H. (2007) The UDP- glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab. Dispos. 35, 2040-2044.
10. Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., and Parkinson, A. (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab. Dispos. 34, 191-197.
11. Sallustio, B. C., and Foster, D. J. (1995) Reactivity of gemfibrozil 1-O-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. Drug Metab. Dispos. 23, 892-899.
12. Hinton, L. K., Galetin, A., and Houston, J. B. (2008) Multiple inhibition mechanisms and prediction of drug-drug interactions: Status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm. Res. 25, 1063-1074.
13. Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., and Baillie, T. A. (2002) Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. 301, 1042-1051.
14. Tornio, A., Niemi, M., Neuvonen, M., Laitila, J., Kalliokoski, A., Neuvonen, P. J., and Backman, J. T. (2008) The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: Evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin. Pharmacol. Ther. 84, 403-411.
15. Fontana, E., Dansette, P. M., and Poli, S. M. (2005) Cytochrome P450 enzymes mechanism based inhibitors: Common sub-structures and reactivity. Curr. Drug Metab. 6, 413-454.
16. Gillam, E. M., Baba, T., Kim, B. R., Ohmori, S., and Guengerich, F. P. (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305, 123-131.
17. Holmans, P. L., Shet, M. S., Martin-Wixtrom, C. A., Fisher, C. W., and Estabrook, R. W. (1994) The high-level expression in Escherichia coli of the membrane-bound form of human and rat cytochrome b5 and studies on their mechanism of function. Arch. Biochem. Biophys. 312, 554-565.
18. Porter, T. D., Wilson, T. E., and Kasper, C. B. (1987) Expression of a functional 78,000 Da mammalian flavoprotein, NADPH-cytochrome P-450 oxidoreductase, in Escherichia coli. Arch. Biochem. Biophys. 254, 353-367.
19. Sajiki, H., Ito, N., Esaki, H., Maesawa, T., Maegawa, T., and Hirota, K. (2005) Aromatic ring favorable and efficient H-D exchange reaction catalyzed by Pt/C. Tetrahedron Lett. 46, 6995-6998.
20. Walsky, R. L., and Obach, R. S. (2004) Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 32, 647-660.
21. Silverman, R. B. (1996) Mechanism-based enzyme inactivators. In Contemporary Enzyme Kinetics and Mechanism (Purich, D., Ed.) pp 291-335, Academic Press, San Diego, CA.
22. Thomas, B. F., Burgess, J. P., Coleman, D. P., Scheffler, N. M., Jeffcoat, A. R., and Dix, K. J. (1999) Isolation and identification of novel metabolites of gemfibrozil in rat urine. Drug Metab. Dispos. 27, 147-157.
23. Baer, B. R., Wienkers, L. C., and Rock, D. A. (2007) Time-dependent inactivation of P450 3A4 by raloxifene: Identification of Cys239 as the site of apoprotein alkylation. Chem. Res. Toxicol. 20, 954-964.
24. Lin, H. L., and Hollenberg, P. F. (2007) The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. J. Pharmacol. Exp. Ther. 321, 276-287.
25. Kuo, C. L., Raner, G. M., Vaz, A. D., and Coon, M. J. (1999) Discrete species of activated oxygen yield different cytochrome P450 heme adducts from aldehydes. Biochemistry 38, 10511-10518.
26. Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J. Biol. Chem. 279, 9497-9503.
27. Schoch, G. A., Yano, J. K., Sansen, S., Dansette, P. M., Stout, C. D., and Johnson, E. F. (2008) Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J. Biol. Chem. 283, 17227-17237.
28. Raner, G. M., Hatchell, A. J., Morton, P. E., Ballou, D. P., and Coon, M. J. (2000) Stopped-flow spectrophotometric analysis of intermediates in the peroxo-dependent inactivation of cytochrome P450 by aldehydes. J. Inorg. Biochem. 81, 153-160.
29. Ortiz de Montellano, P. R. (1990) Free radical modification of prosthetic heme groups. Pharmacol. Ther. 48, 95-120.
30. Guengerich, F. P. (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14, 611-650.
31. Wojciechowski, G., and de Montellano, P. R. (2007) Radical energies and the regiochemistry of addition to heme groups. Methylperoxy and nitrite radical additions to the heme of horseradish peroxidase. J. Am. Chem. Soc. 129, 1663-1672.
32. Choe, Y. S., and Ortiz de Montellano, P. R. (1991) Differential additions to the myoglobin prosthetic heme group. Oxidative gamma-meso substitution by alkylhydrazines. J. Biol. Chem. 266, 8523-8530.
33. Kunze, K. L., and Trager, W. F. (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656.
34. Racha, J. K., Rettie, A. E., and Kunze, K. L. (1998) Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: Detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry 37, 7407-7419.
35. Khursan, S. L., Mikhailov, D. A., Yanborisov, V. M., and Borisov, D. I. (1997) AM1 calculations of bond dissociation energies. Allylic and benzylic C-H bonds. React. Kinet. Catal. Lett. 61, 91-95.
36. Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., and McLeod, H. L. (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44, 279-304.
37. Nelson, S. D., and Trager, W. F. (2003) The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab. Dispos. 31, 1481-1498.
38. Ling, K. H., and Hanzlik, R. P. (1989) Deuterium isotope effects on toluene metabolism. Product release as a rate-limiting step in cytochrome P-450 catalysis. Biochem. Biophys. Res. Commun. 160, 844-849.
39. Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. P., and Yokoi, T. (1999) Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 27, 1260-1266.